期刊
JOURNAL OF NANOPARTICLE RESEARCH
卷 13, 期 4, 页码 1449-1465出版社
SPRINGER
DOI: 10.1007/s11051-011-0237-y
关键词
Nanomedicine; Human subjects research; Research oversight; Exceptional oversight; IRBs; Governance
资金
- National Science Foundation (NSF) [SES-0608791]
- National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI) [1RC-1HG005338-01]
- NIH
The basic procedures and rules for oversight of U.S. human subjects research have been in place since 1981. Certain types of human subjects research, however, have provoked creation of additional mechanisms and rules beyond the Department of Health & Human Services (DHHS) Common Rule and Food and Drug Administration (FDA) equivalent. Now another emerging domain of human subjects research-nanomedicine-is prompting calls for extra oversight. However, in 30 years of overseeing research on human beings, we have yet to specify what makes a domain of scientific research warrant extra oversight. This failure to systematically evaluate the need for extra measures, the type of extra measures appropriate for different challenges, and the usefulness of those measures hampers efforts to respond appropriately to emerging science such as nanomedicine. This article evaluates the history of extra oversight, extracting lessons for oversight of nanomedicine research in human beings. We argue that a confluence of factors supports the need for extra oversight, including heightened uncertainty regarding risks, fast-evolving science yielding complex and increasingly active materials, likelihood of research on vulnerable participants including cancer patients, and potential risks to others beyond the research participant. We suggest the essential elements of the extra oversight needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据